HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth

Hims & Hers Health (HIMS) reported strong first-quarter 2025 results driven by its subscription-based model, with subscriber count up 38.4% year-over-year to 2.4 million and online revenue increasing 115.3% to $576.4 million. The company's focus on personalized care and upselling premium services, including GLP-1 weight loss offerings, boosted monthly online revenue per average subscriber by 52.7% to $84, and deferred revenues reached $110.8 million. HIMS shares have surged 138.1% year-to-date, significantly outperforming the industry, and the Zacks Consensus Estimate projects a 170.4% EPS improvement for 2025.

Analysis

Hims & Hers Health, Inc. (HIMS) reported robust first-quarter 2025 financial results, driven by the success of its subscription-based direct-to-consumer healthcare model. Subscriber numbers reached 2.4 million, a 38.4% year-over-year increase, which translated into online revenues of $576.4 million, up 115.3% year-over-year and forming the bulk of its $586 million total revenue. The company's ability to deepen customer engagement is evident in the 52.7% year-over-year growth in Monthly Online Revenue per Average Subscriber to $84, supported by upselling premium services, including newly launched GLP-1 weight loss offerings and partnerships with entities like Novo Nordisk. A significant $110.8 million in deferred revenues as of March 2025 underscores future revenue visibility. This subscription focus mirrors strategies at peers like LifeMD (LFMD), with 86% of Q1 2025 revenue from subscriptions, and Doximity (DOCS), where enterprise subscriptions constitute over 95% of fiscal 2025 revenue. HIMS's stock has reflected this operational strength, surging 138.1% year-to-date, substantially outpacing the industry's 29.7% gain. Its forward 12-month Price-to-Sales (P/S) ratio stands at 5X, which is below the industry average of 6.3X but significantly higher than its own five-year median of 2.6X, and it carries a Zacks Value Score of C, suggesting valuation warrants attention. Analysts project a 170.4% improvement in HIMS's 2025 earnings per share, and the stock holds a Zacks Rank #2 (Buy).

Key Decisions for Investors

• Investors should acknowledge HIMS's strong Q1 2025 performance, characterized by significant subscriber and average revenue per user growth, alongside a positive Zacks #2 (Buy) rating and a projected 170.4% EPS increase for 2025.
• Careful consideration of the current valuation is warranted; while the forward P/S of 5X is below the industry average, it is considerably above HIMS's historical five-year median, the stock has surged 138.1% year-to-date, and it holds a neutral Value Score of C.
• Monitor the company's ability to sustain its high growth trajectory, particularly in upselling new offerings like GLP-1 treatments and maintaining subscriber retention, as these factors are crucial for justifying its elevated valuation and supporting further appreciation.